News

News

Press releases

March 21, 2018
Kyn Therapeutics Appoints Chairman and Scientific Advisory Board Member

December 14, 2017
Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways

view all Tweets

Twitter

@KynTherapeutics
We’re back from #AACR18 in Chicago. It was a great week, full of incredibly productive sessions with leading cancer… http://jyEX0zjWop

@KynTherapeutics
The Kyn Team is presenting our IDO/TDO programs at #AACR18 today. Here is Karen McGovern, VP Drug Discovery, handl… http://t1f6X54XZ5

@KynTherapeutics
We will present preclinical studies of compelling targets linked to immune modulation and share our posters on the… http://IpvyGz55Nr

Media contact

Tom Donovan
Ten Bridge Communications
857-559-3397
tom@tenbridgecommunications.com

Alerts

Sign up to get up-to-date news about Kyn Therapeutics.

Contact us

Find us

Kyn Therapeutics
1030 Massachusetts Avenue
Suite 400
Cambridge, MA 02138

Call us

1-857-273-8343

Email us

info@kyntherapeutics.com

Friend us

LinkedIn